Ruxolitinib: a targeted treatment option for patients with polycythemia vera
Blood and Lymphatic Cancer: Targets and Therapy · 2016
DOI: 10.2147/blctt.s101185 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood and Lymphatic Cancer: Targets and Therapy, 2016. Verfasst von Kris Vaddi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery, Incyte Corporation, Wilmington, DE, kvaddi@incyte.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Drug Discovery, Incyte Corporation, Wilmington, DE, kvaddi@incyte.com.
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Clinical Investigations Center, Hôpital Saint-Louis et Université Paris Diderot, Paris, France.
Zitieren
APA
Vaddi, K., Verstovsek, S., & Kiladjian, J. J. (2016). Ruxolitinib: a targeted treatment option for patients with polycythemia vera. Blood and Lymphatic Cancer: Targets and Therapy. https://doi.org/10.2147/blctt.s101185
Vancouver
Vaddi K, Verstovsek S, Kiladjian JJ. Ruxolitinib: a targeted treatment option for patients with polycythemia vera. Blood and Lymphatic Cancer: Targets and Therapy. 2016. doi:10.2147/blctt.s101185
BibTeX
@article{Vaddi2016,
author = {Vaddi, Kris and Verstovsek, Srdan and Kiladjian, Jean-Jacques},
title = {Ruxolitinib: a targeted treatment option for patients with polycythemia vera},
journal = {Blood and Lymphatic Cancer: Targets and Therapy},
year = {2016},
doi = {10.2147/blctt.s101185}
}
EUVIMED